Expression of Apoptosis Related and Proliferative Proteins in Malignant Lympho-Proliferative Disorders

Overview

Journal Iran J Pathol

Date 2018 Mar 14

PMID 29531548

Citations 4

Authors

Zeeba S Jairajpuri

Rekha Ghai

Sumita Saluja

Sujala Kapur

K T Bhowmik

Affiliations

Soon will be listed here.

Abstract

Background & Objective: The current study aimed to perform an immunohistochemical analysis of patterns of apoptotic and cell proliferative related protein expression in different histological grades and immune phenotypes of malignant lymphomas and other lymphoproliferative disorders.

Methods: This observational study was carried on 60lymph node biopsies of lymphoproliferative disorders. The biopsies were analyzed histologically and immunohistochemically.

Results: A total of 60 lymph node biopsies were included in the study, of which 81.6% were of malignant lympho-proliferative lesions. The majority of the biopsies were B-cell (66%) and were grouped in the intermediate grade. Bax and BCL-2 protein expression was presented by percentage of immune positive neoplastic cells per 10fields and graded on a scale of 1 to4. A Bcl-2, Bax Protein Ratio (BBPR) was determined for each case by dividing the estimated Bcl-2 protein (percentage of Bcl-2 positive cells x Bcl-2 staining intensity) by the estimated Bax protein (percentage of Bax positive cells x Bax immunostaining intensity). The mean BBPR was found to be significantly higher in indolent lymphomas (2.64 ± 1.3) as compared to aggressive lymphomas (0.47 ± 0.9) (P<0.01). The expression of P53 and PCNA in 35 biopsies of Non Hodgkin Lymphomas (NHL) was found to increase from low to high grade tumors.

Conclusions: A significant correlation was found between BBPR and predicted biological behavior of indolent and aggressive lymphomas. This indicates the important role of Bcl-2 and Bax in biological behavior of lymphomas. Furthermore, P53 and PCNA expression were found to increase from low to high-grade tumors suggesting their prognostic value in NHL.

Citing Articles

Protective effect of cerium oxide on testicular function and oxidative stress after torsion/detorsion in adult male rats.

Yesil S, Ozdemir C, Arslan M, Cakir Gundogdu A, Kavutcu M, Atan A Exp Ther Med. 2022; 25(1):1.

PMID: 36561629 PMC: 9748645. DOI: 10.3892/etm.2022.11700.

Immunophenotypic characterisation of non-Hodgkin lymphomas at a tertiary hospital in Ghana.

Adomako J, Abrahams A, Dei-Adomakoh Y Ecancermedicalscience. 2022; 16:1458.

PMID: 36405938 PMC: 9666277. DOI: 10.3332/ecancer.2022.1458.

Effect of Moxibustion on Testosterone Secretion and Apoptosis of Spermatogenic Cells in Aging Rats.

Yao C, Zhao C, Zhang S, Liu S Evid Based Complement Alternat Med. 2019; 2019:5186408.

PMID: 31885650 PMC: 6925733. DOI: 10.1155/2019/5186408.

Ginsenoside Compound K Regulates Amyloid β via the Nrf2/Keap1 Signaling Pathway in Mice with Scopolamine Hydrobromide-Induced Memory Impairments.

Yang Q, Lin J, Zhang H, Liu Y, Kan M, Xiu Z J Mol Neurosci. 2018; 67(1):62-71.

PMID: 30535776 DOI: 10.1007/s12031-018-1210-3.

References

Wheaton S, Netser J, Guinee D, Rahn M, Perkins S . Bcl-2 and bax protein expression in indolent versus aggressive B-cell non-Hodgkin's lymphomas. Hum Pathol. 1998; 29(8):820-5. DOI: 10.1016/s0046-8177(98)90451-8. View

Brousset P, Benharroch D, Krajewski S, Laurent G, Meggetto F, Rigal-Huguet F . Frequent expression of the cell death-inducing gene Bax in Reed-Sternberg cells of Hodgkin's disease. Blood. 1996; 87(6):2470-5. View

Sahu S, Choudhuri T . Lack of association between Bax promoter (-248G>A) single nucleotide polymorphism and susceptibility towards cancer: evidence from a meta-analysis. PLoS One. 2013; 8(10):e77534. PMC: 3798304. DOI: 10.1371/journal.pone.0077534. View

Marafioti T, Hummel M, Foss H, Laumen H, Korbjuhn P, Anagnostopoulos I . Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood. 2000; 95(4):1443-50. View

Kanavaros P, Stefanaki K, Vlachonikolis J, Eliopoulos G, Kakolyris S, Rontogianni D . Expression of p53, p21/waf1, bcl-2, bax, Rb and Ki67 proteins in Hodgkin's lymphomas. Histol Histopathol. 2000; 15(2):445-53. DOI: 10.14670/HH-15.445. View

Gaulard P, DAgay M, Peuchmaur M, Brousse N, Gisselbrecht C, Solal-Celigny P . Expression of the bcl-2 gene product in follicular lymphoma. Am J Pathol. 1992; 140(5):1089-95. PMC: 1886507. View

Burra U, Shanthi P, Krishnan K, Madhavan M . P 53 and PCNA in Non Hodgkin's lymphoma--an immunohistochemical evaluation. Indian J Pathol Microbiol. 2003; 43(1):61-4. View

Miyashita T, Harigai M, Hanada M, Reed J . Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994; 54(12):3131-5. View

Korsmeyer S, Shutter J, Veis D, Merry D, Oltvai Z . Bcl-2/Bax: a rheostat that regulates an anti-oxidant pathway and cell death. Semin Cancer Biol. 1993; 4(6):327-32. View

10.

Canioni D, Jabado N, MacIntyre E, Patey N, Emile J, Brousse N . Lymphoproliferative disorders in children with primary immunodeficiencies: immunological status may be more predictive of the outcome than other criteria. Histopathology. 2001; 38(2):146-59. DOI: 10.1046/j.1365-2559.2001.01039.x. View

11.

Rabenhorst S, Burini R, Schmitt F . Proliferating cell nuclear antigen (PCNA) in non-Hodgkin's lymphomas: correlation with working formulation and Kiel classification in formalin-fixed paraffin-embedded material. Pathology. 1996; 28(1):12-6. DOI: 10.1080/00313029600169423. View

12.

Gascoyne R, Krajewska M, Krajewski S, Connors J, Reed J . Prognostic significance of Bax protein expression in diffuse aggressive non-Hodgkin's lymphoma. Blood. 1997; 90(8):3173-8. View

13.

Charalambous G, Gomatos I, Konstadoulakis M, Messaris E, Manouras A, Apostolou A . Protein expression of bax, bcl-2, and p53 in patients with non-Hodgkin's gastric lymphoma: prognostic significance. World J Surg. 2000; 24(5):608-14. DOI: 10.1007/s002689910098. View

14.

Soini Y, Paakko P . Apoptosis and expression of caspases 3, 6 and 8 in malignant non-Hodgkin's lymphomas. APMIS. 1999; 107(11):1043-50. DOI: 10.1111/j.1699-0463.1999.tb01508.x. View

15.

KERR J, Winterford C, Harmon B . Apoptosis. Its significance in cancer and cancer therapy. Cancer. 1994; 73(8):2013-26. DOI: 10.1002/1097-0142(19940415)73:8<2013::aid-cncr2820730802>3.0.co;2-j. View

16.

Derenzini E, Younes A . Predicting treatment outcome in classical Hodgkin lymphoma: genomic advances. Genome Med. 2011; 3(4):26. PMC: 3129642. DOI: 10.1186/gm240. View

17.

Ng S, Davids M . Selective Bcl-2 inhibition to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma. Clin Adv Hematol Oncol. 2014; 12(4):224-9. View

18.

Winter J, Andersen J, Reed J, Krajewski S, Variakojis D, Bauer K . BCL-2 expression correlates with lower proliferative activity in the intermediate- and high-grade non-Hodgkin's lymphomas: an Eastern Cooperative Oncology Group and Southwest Oncology Group cooperative laboratory study. Blood. 1998; 91(4):1391-8. View

19.

Hussein M, Al-Sabae T, Georgis M . Analysis of the Bcl-2 and p53 protein expression in the lymphoproliferative lesions in the upper Egypt. Cancer Biol Ther. 2005; 4(3):324-8. DOI: 10.4161/cbt.4.3.1568. View

20.

Kim H, Hendrickson R, DORFMAN R . Composite lymphoma. Cancer. 1977; 40(3):959-76. DOI: 10.1002/1097-0142(197709)40:3<959::aid-cncr2820400302>3.0.co;2-3. View